✦ LIBER ✦

PP-5-1 Preliminary analysis of a randomized phase II study of high-dose chemotherapy in high-risk breast cancer

✍ Scribed by E.J.Th. Rutgers; D.J. Richel; J.W. Baars; J.H. Schornagel; J.H. Borger; C.C.E. Koning; S. Rodenhuis

Book ID: 116168148
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 168 KB
Volume: 32
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(96)84164-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

0-29. A randomized phase II study of hig

0-29. A randomized phase II study of high-dose chemotherapy in high-risk breast cancer

✍ E. Rulgers; D.J. Richel; J.W. Baars; E. van der Wall; J.H. Schornagel; C. Schaak 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 306 KB

Randomized studies of high-dose chemothe

Randomized studies of high-dose chemotherapy in high-risk breast cancer in The Netherlands

✍ S. Rodenhuis; E.G.E. De Vries 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 161 KB

662 - Dose-intensified versus standard c

662 - Dose-intensified versus standard chemotherapy in high-risk breast cancer patients: Preliminary data of a randomized trial

✍ C. Thomssen; M. Untch; E. Schill; D. Sattler; G. Konecny; P. Bauernfeind; F. Jän 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 266 KB

A phase II study of high-dose medroxypro

A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer

✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high

400 Dose-dense sequential adriamycin-pac

400 Dose-dense sequential adriamycin-paclitaxel-cyclophosphamide (A-T-C) chemotherapy in high-risk early breast cancer — a phase II study

✍ Z. Kahán; G. Uhercsák; R. Hajnal-Papp; K. Boda; L. Thurzó 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Phase I–II study of high-dose etoposide

Phase I–II study of high-dose etoposide in patients with refractory breast cancer

✍ Giuseppe Fraschini; Frankie A. Holmes; Laura Esparza; Richard L. Theriault; Aman 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 162 KB